

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

PA/4-32723A

APPLICATION NO.

10,531,677

APPLICANT

MARGARET FORNEY PRESCOTT

FILING DATE

April 15, 2005

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,157,027	10-1992	Biller et al.			
	AB	2003/0064965	04-2003	Richter, Jacob			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 00 03677	1/27/00	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 01 49295	7/12/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	YLITALO: "Bisphosphonates and atherosclerosis" GENERAL PHARMACOLOGY, vol. 35, 2002, pages 287-296
	AS	PRICE ET AL.: "bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption" Arteriosclerosis, Thrombosis And Vascular Biology, vol. 21, no. 5, 2001
	AT	KOSHIYAMA HIROYUKI ET AL.: "Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes" Journal Of Clinical Endocrinology And Metabolism, vol. 85, no. 8, August 2000

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
PA/4-32723A
APPLICATION NO.
10,531,677
APPLICANT
MARGARET FORNEY PRESCOTT
FILING DATE
April 15, 2005

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	YLITALO RITVA ET AL: "Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate" Pharmacology And Toxicology, vol. 90, no. 3, March 2002 (2002-03), pages 139-143
	DB	JAGDEV S P ET AL: "The Bisphosphonate, Zoledronic Acid, Induces Apoptosis Of Breast Cancer Cells: Evidence For Synergy With Paclitaxel" British Journal Of Cancer, London, GB, vol. 8, no. 84, 2001, pages 1126-1134
	DC	LEVY R J ET AL: "Polymeric drug delivery systems for treatment of cardiovascular calcification, arrhythmias and restenosis" Journal OfControlled Release, Elsevier Science Publishers B.V. Amsterdam, NL, vol. 36, no. 1, 1 September 1995, pages 137-147
	DD	BURNETT ET AL.: "cardiovascular disease and osteoporosis: is there a link between lipids and bone" Annals Of Clinical Biochemistry, vol. 39, April 2002 (2002-04), pages 203-210
	DE	Yitalo et al., "Accumulation of fisphosphonates in the aoeta and some other tissues of healthy and atherosclerotic rabbits", 1996m J Lab clin Med, Volume 127, Number 2, Pages 200-206.
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.